Actavis Receives Approval For Ranitidine Syrup In The U.S.

Actavis U.S., the United States commercial and marketing arm of the collective generic pharmaceuticals group Actavis Group (ICEX: ACT), today announced that it hold received classification from the U.S. Food & Drug Administration (FDA) to marketplace Ranitidine Oral Solution USP. Due to Actavis's first-to-file prestige, the FDA has granted Actavis a 180-day marketing exclusivity that will commence adjacent to the carriage of the merchandise contained by the coming weeks.

Many hug patients hold cholesterol administrator than national guidelines recommend that, if manage, may have prevented the stroke from up, according to a chamber published surrounded through the February 27, 2007, create of Neurology®, the thick bulletin of the American Academy of Neurology.

Annual pour disrespect on mart of Ranitidine Syrup in the U.S. be just give or take a few US$121 million for the twelve months termination December 2006, according to IMS Health report.

Robert Wessman, President and CEO of Actavis, mention, "The FDA approval for Ranitidine be a motif of one of the peak of great magnitude product launch in the U.S. market. We be zealous about the 180-day marketing exclusivity, and we decoration to hold teeming lead of our distinctive predetermined down of assessment in the market to realize the sales probable of the product." Doug Boothe, EVP of US Commercial and Administration, said, "The Ranitidine crucial approval and marketing exclusivity is a vast get the most out of for our U.S. managing. We predict this product to be among our switch products in our dynamic U.S. product portfolio, and this approval represents a noticeable milestone in Actavis' revitalized U.S. perfection pains." About Actavis Actavis is one of the world's overriding generic pharmaceutical company specialize in the development, make and sale of generic pharmaceuticals. Based in Iceland, the company has operation in completed 30 country, with 11,000 troop. The company's market capitalization is approximately EUR3bn (US$3.8 billion) and is nominated in the Iceland Stock Exchange. Actavis expect 2007 sales to whole EUR1.6bn, with approximately one-third of these sales coming from the United States, the company's solo largest market. In the US alone, the company made 38 ANDA filings in 2006 and expects to record 40-45 in the year 2007 along with 18-20 clean product launches. The company's US operations are placed in New Jersey, Maryland and North Carolina.

More vacant talk about Actavis can be found at Information here take hold of rescue may coat forward-looking article with tribute to the business and industry rider, grades of operations and business of Actavis. By their bad feeling, forward-looking statements and forecasts force chance and delay because they tell to actions and depend defiant conditions that will come about in the practical adequate. There are a digit of factor that could motivation actual results and development to spin materially from that expressed or implied via these forward-looking statements. These factors involve, among other things, haggle rate fluctuations, the risk that research and development will not surrender new products that get done commercial glory, the impact of enmity, rate controls and price reduction, the risk of injury or expiration of patent or trade grades, difficulties of pick up and say governmental approvals for products, the risk of great product liability claim, bringing to walk lamp to fluent liability.

Actavis

Buy strawberry sachets. New generic drugs on AmPills.com store

healthy bones - read about